Trend-Following Backtester · Guide · backtest 한국어

equity · KR

삼성바이오로직스 backtest

10 trend-following strategies were compared on the full daily history of 삼성바이오로직스. 0 beat buy-and-hold CAGR; Supertrend ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is Supertrend (CAGR 18.0%, MDD -43.9%).

Data 2016-11-11 ~ 2026-07-31daily bars 2,378 (9.7 years)Costs 0.5%Venue XKRXMonthly snapshot 2026-07-31

Results by strategy

0 of 10 beat buy and hold (CAGR 20.3%, drawdown -57.3%).

Sharpe leader (same as main): Supertrend — CAGR 18.0%, MDD -43.9%, Sharpe 0.78, 56% exposure.

Return/drawdown alternative: Supertrend — CAGR is 2.2%p lower than buy and hold, while drawdown improves by 13.4%p (CAGR 18.0%, MDD -43.9%, exposure 56%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
Supertrend
period=26, mult=3.9
18.0%-43.9%0.780.415.0x4156%
MACD
fast=13, slow=29, signal=17
16.6%-37.9%0.720.444.4x11750%
Donchian 채널 돌파
entryN=30, exitN=14
13.6%-43.9%0.710.313.5x4740%
Keltner 채널 돌파
emaPeriod=49, atrPeriod=12, mult=2.2
12.0%-36.1%0.640.333.0x4038%
볼린저 밴드 돌파
n=50, k=2
11.2%-29.8%0.610.382.8x3335%
ADX / DI 방향성
period=28, threshold=15
12.0%-43.6%0.610.283.0x5441%
SMA 크로스오버
fast=24, slow=107
12.4%-45.4%0.570.273.1x2851%
EMA 크로스오버
fast=54, slow=85
12.4%-43.7%0.550.283.1x2257%
Parabolic SAR
step=0.005, maxStep=0.3
8.2%-45.6%0.430.182.1x7556%
ROC 모멘텀
n=121, threshold=0.01
7.0%-56.6%0.380.121.9x10858%
Buy and hold20.3%-57.3%0.690.356.0x1100%
1x 2017 2019 2021 2023 2025 SupertrendBuy and hold
Supertrend: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -14% -29% -43% -57% 2017 2019 2021 2023 2025 Buy and holdSupertrend
Supertrend maximum drawdown -43.9% (2021-08-17 → 2024-07-08), prior peak not yet recovered.

Rules of the top strategy

Trades the direction of a volatility-based trend line that trails below/above price.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next